|drug3738||Standard of care Wiki||0.20|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The aim of the study will be to determine the epidemiological and clinical features of COVID-19 cases, immunological and virological courses, interaction with nutritional status, and response to treatment for COVID-19 patients admitted to treatment centers in Ethiopia. Methods: This multi-site cohort enrolls, patients with confirmed COVID-19 infection admitted to treatment centers will be enrolled irrespective of their symptoms and followed up for 12 months. Baseline epidemiological, clinical, laboratory and imaging data will be collected from treatment records, interviews, physical measurements and biological samples. Endline data involves treatment and prognostic outcomes to be measured using different biomarkers and clinical parameters, The patients will be followed up in the selected treatment centers for COVID-19 infection. For all data collected both descriptive and multivariable analyses will be performed to isolated determinants of the treatment outcome and prognosis to generate relevant information for informed prevention and case management.
Description: Number patients developing severe infection or deathMeasure: Number of patients survival or death Time: 12 months
Description: Mean rate of recovery in patients with diagnosis of COVID-19Measure: Rate of recovery time Time: 4 weeks
Description: proportion of shedding detected in environment and personal protective equipmentMeasure: Viral shedding Time: 6 weeks
Description: quantity of viral loadMeasure: Viral loads Time: 12 months
Description: clinical manifestations Proportions of mild, moderate, severe and critical casesMeasure: Clinical symptoms and signs Time: 12 months
Description: Force exerted by the blood against the walls of the vessels (arteries) as it is pumped by the heart. Measurement using the multi-parameter vital signs monitor. Units of measurement in mmHg. Obtain systolic and diastolic pressure.Measure: Blood pressure Time: 4 weeks
Description: Prevalence of severe forms among all COVID-19 patients with diabetesMeasure: Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19 Time: 4 weeks
Description: proportion of patients with cancer and COVID-19 postiveMeasure: Assess the prevalence of severe forms among hospitalized patients with cancer and COVID-19 Time: 4 weeks
Description: TC, TG, HDL-C, and LDL-CMeasure: Lipid Profiles Time: 12 months
Description: Prevalence of inadequate intake of zinc, Iron and Vitamin AMeasure: Assess the prevalence of nutrient intakes Time: 12 months
Description: Prevalence of Vitamin D, zinc, and Iron deficiency anemia measured in serumMeasure: Assess the prevalence of micronutrients deficiencies among hospitalized patients with COVID-19 Time: 12 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports